Calithera Biosciences, Inc.

CALA

US13089P5070

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 08:09:44 07/06/2024 pm IST			5-day change	1st Jan Change
0.02 ^USD	0.00%		+100.00%	-33.33%

2023	Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	CI
2023	North American Morning Briefing : Stock Futures -2-	DJ

Calithera Biosciences, Inc. Announces Resignation of Curtis Hecht, Chief Business Officer, Effective April 2, 2021

March 17, 2021 at 02:06 am IST

Calithera Biosciences, Inc. on March 12, 2021, Curtis Hecht, Chief Business Officer of the Company, notified the Company of his decision to resign from his position effective April 2, 2021.

Latest news about Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	14/23/14	CI
North American Morning Briefing : Stock Futures -2-	23/23/23	DJ
North American Morning Briefing : Retail Sales, -2-	16/23/16	DJ
Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Calithera Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from S&P TMI Index	06/23/06	CI
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite Index	01/23/01	CI
Top Premarket Decliners	25/23/25	MT
Calithera Biosciences Shares Set to be Suspended From Nasdaq on Feb. 2; Stock Declines Premarket	25/23/25	MT
Top Midday Decliners	10/23/10	MT
Calithera Biosciences to Proceed With Liquidation and Dissolution of Company	09/23/09	MT
Calithera Biosciences, Inc. Announces Departure of Susan M. Molineaux as Chief Executive Officer	09/23/09	CI
Calithera Biosciences, Inc. Announces Departure of Stephanie Wong as Chief Financial Officer	09/23/09	CI
Calithera Biosciences, Inc. Announces Executive Departures	09/23/09	CI
Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; Shares Climb 10%	05/23/05	MT
Antengene Corporation Limited Enters into Assignment Agreement with Calithera Biosciences, Inc. to Acquire All Outstanding Rights of ATG-037	04/23/04	CI
North American Morning Briefing : Stock Futures -2-	16/22/16	DJ
Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral From Buy	15/22/15	MT
SVB Securities Downgrades Calithera Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $18	15/22/15	MT
Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Transcript : Calithera Biosciences, Inc., Q3 2022 Earnings Call, Nov 14, 2022	15/22/15
Calithera Biosciences, Inc. cancelled the transaction announced on October 18, 2021	18/22/18	CI
Health Care Up Amid Deal Activity -- Health Care Roundup	04/22/04	DJ
Calithera Biosciences Receives FDA's Fast Track Designation for Lung Cancer Drug Candidate; Shares Climb	03/22/03	MT
Calithera Biosciences, Inc. Receives U.S. Food & Drug Administration Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer	03/22/03	CI

Chart Calithera Biosciences, Inc.

Duration

Period

More charts

Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CALITHERA BIOSCIENCES, INC.	-33.33%	97.45K
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B

Other Pharmaceuticals

Calithera Biosciences, Inc.

Equities

CALA

US13089P5070

Pharmaceuticals

Calithera Biosciences, Inc. Announces Resignation of Curtis Hecht, Chief Business Officer, Effective April 2, 2021

Latest news about Calithera Biosciences, Inc.

Chart Calithera Biosciences, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals